StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Nektar Therapeutics's price to sales ratio was 14.2× on Nov 11, 2026, against 20.5× a year earlier. Over the last 5 years it ranged from 1.0× to 31.4×, with a median of 4.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202614.2×+0.9
2025Dec 31, 202513.3×+11.4
2024Dec 31, 20241.8×+0.6
2023Dec 29, 20231.2×−3.3
2022Dec 30, 20224.5×−20.4
2021Dec 31, 202124.8×+6.2
2020Dec 31, 202018.7×−12.8
2019Dec 31, 201931.5×+26.9
2018Dec 31, 20184.6×−33.0
2017Dec 29, 201737.5×+27.4
2016Dec 30, 201610.1×−0.5
2015Dec 31, 201510.6×+1.3
2014Dec 31, 20149.4×−0.1
2013Dec 31, 20139.5×−1.4
2012Dec 31, 201210.9×+4.6
2011Dec 30, 20116.3×–

More Nektar Therapeutics figures

See a number that looks wrong?